Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anvumetostat in Combination With IDE397 in Advanced MTAP-null Solid Tumors
NCT05975073Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of anvumetostat and IDE397 in non-small cell lung cancer (NSCLC) and solid tumor (2 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities, Treatment-emergent Adverse Events and 2 more. Started Aug 2023; status: completed.
02
Drugs
anvumetostatIDE397
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05975073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975073.